The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 06, 2018

Filed:

Feb. 18, 2016
Applicant:

Biontech Ag, Mainz, DE;

Inventors:

Özlem Türeci, Mainz, DE;

Ugur Sahin, Mainz, DE;

Gerd Helftenbein, Gemunden, DE;

Volker Schlüter, Neuried, DE;

Assignee:

BioNTech AG, Mainz, DE;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
G01N 33/574 (2006.01); C07K 14/47 (2006.01); C07K 14/705 (2006.01); C07K 16/30 (2006.01); C12Q 1/68 (2018.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
G01N 33/57492 (2013.01); C07K 14/4748 (2013.01); C07K 14/705 (2013.01); C07K 16/30 (2013.01); C12Q 1/6886 (2013.01); A61K 2039/505 (2013.01); C07K 2317/34 (2013.01); C12Q 2600/112 (2013.01); C12Q 2600/158 (2013.01); G01N 2800/56 (2013.01);
Abstract

The present invention provides agents with tumor-inhibiting activity, and which are selective for cells expressing or abnormally expressing a tumor-associated antigen. Said tumor-associated antigen has a nucleotide sequence selected from the group consisting of: (a) a nucleotide sequence selected from the specific sequences set forth herein, or a 6-50 contiguous nucleotide residue portion thereof; (b) a nucleotide sequence of a nucleic acid which hybridizes with a nucleic acid having the nucleotide sequence of (a) under stringent conditions; (c) a nucleotide sequence which is degenerate with respect to the nucleotide sequence of (a) or (b); and (d) a nucleotide sequence which is complementary to the nucleotide sequence of (a), (b) or (c). Pharmaceutical compositions and kits comprising the agents are also provided, as well as methods treating, diagnosing or monitoring a disease characterized by expression or abnormal expression of the tumor-associated antigen.


Find Patent Forward Citations

Loading…